T-ALL,T-LBL , CD7,CAR-T
Showing 1 - 25 of >10,000
T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)
Recruiting
- T-lymphoblastic Lymphoma
- T-ALL
- CAR-T
-
Shanghai, ChinaShanghai Ruijin Hospital
Nov 14, 2023
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Xuzhou, Jiangsu, ChinaAffiliated hospital of Xuzhou medical college
Jun 7, 2023
Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +3 more
- RD13-02 cell infusion
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023
Tumors, Hematologic Tumors, Hematologic Diseases Trial in Hefei (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +2 more
- RD13-02 cell infusion
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of University of Science and Techn
Jun 5, 2023
Leukemia, T Cell Trial in Beijing (CD7 CART)
Recruiting
- Leukemia, T Cell
- CD7 CART
-
Beijing, Hebei, ChinaHe bei Yan da Lu dao pei Hospital
May 24, 2022
T-cell Acute Lymphoblastic Leukemia/Lymphoma Trial in Beijing (Senl-T7)
Recruiting
- T-cell Acute Lymphoblastic Leukemia/Lymphoma
- Senl-T7
-
Beijing, Hebei, ChinaHebei yanda Hospital
Nov 22, 2022
T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma Trial in Kunming (Target CD7 CAR-T cells)
Withdrawn
- T-cell Acute Lymphoblastic Leukemia
- T-lymphoblastic Lymphoma
- Target CD7 CAR-T cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Nov 23, 2022
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Australia, United States (WU-CART-007)
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- WU-CART-007
-
Duarte, California
- +7 more
Jun 22, 2022
T Cell Lymphoblastic Lymphoma Trial in Beijing (BT-007 CD7 CAR-T cells)
Recruiting
- T Cell Lymphoblastic Lymphoma
- BT-007 CD7 CAR-T cells
-
Beijing, ChinaBeijing Cancer Hospital
Sep 22, 2022
T-Cell Acute Lymphocytic Leukemia Trial in Langfang (CD7 CAR-T)
Recruiting
- T-Cell Acute Lymphocytic Leukemia
- CD7 CAR-T
-
Langfang, Hebei, ChinaHebei Yanda Hospital
Jun 26, 2023
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023
T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- CD7 CAR-T cells
-
Shenzhen, Guangdong, ChinaLi Yu
Nov 11, 2022
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +3 more
- Universal CD7-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 17, 2023
Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CAR-T Therapy
-
Hefei, Anhui, China
- +7 more
Jul 31, 2023
Hematologic Diseases, Tumors Trial in Hangzhou (CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation)
Recruiting
- Hematologic Diseases
- Neoplasms
- CD7 CAR-T cells injection
- Allogeneic hematopoietic stem cell transplantation
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Apr 11, 2023
Hematological Malignancies Trial (Anti-CD7 CAR-T)
Not yet recruiting
- Hematological Malignancies
- Anti-CD7 CAR-T
- (no location specified)
Jul 8, 2022
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Azacitidine Injection
- +2 more
- (no location specified)
Oct 15, 2023
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma Trial in Langfang (CD7CAR T cells)
Recruiting
- Relapsed/Refractory, High Risk Hematologic Malignancies
- T-ALL/Lymphoma
- CD7CAR T cells
-
Langfang, Hebei, ChinaHebei Yanda Lu Daopei Hospital
Jun 30, 2022
T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- +4 more
- anti-CD7 CAR-T cells
-
Shanghai, ChinaXianmin General Song
Aug 29, 2022
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
T-cell Acute Lymphoblastic Leukemia Trial in Beijing (CD5 CAR-T)
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- CD5 CAR-T
-
Beijing, Beijing, ChinaXuanwu Hospital Capital Medical University
Oct 23, 2022
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 17, 2023
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 25, 2023
CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)
Recruiting
- CD7+ Acute Leukemia
- CD7+ Lymphoma
- anti-CD7 CAR-T
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
Sep 18, 2022